Knowledge Center

From Discovery to Delivery: Insights and Technologies Shaping Drug Manufacturing

Knowledge

Our Knowledge Center

At Sinopep, we are committed to advancing the frontiers of peptides, oligonucleotides, and small molecules as transformative therapeutic solutions. As a leader in pharmaceutical research, development, and manufacturing, we aim to set new standards across the industry. Our relentless focus on innovation, operational excellence, and scalable manufacturing has positioned us at the forefront of the global pharmaceutical landscape—delivering life-saving solutions and driving progress for our partners worldwide.

News Press Releases

Sinopep News

Latest press releases, news, and publications.

whitepaper icon

White Papers

In-house scientific publications from Sinopep.

Sinopep Events

Events

Upcoming events and conference exhibitions.

Publications from Sinopep

Publications

Peer-reviewed publications from Sinopep.

video icon

Videos

Corporate videos, seminars, and public events.

Insights and articles from Sinopep

Articles and Insights

Short articles and insights from Sinopep.

Brochure Icon

Brochures

GMP and discovery products and services.

FAQ icon

FAQS

Frequently Asked Questions (FAQs) about our products and services.

Full-Service Peptide CDMO

Sinopep is a trusted CDMO specializing in end-to-end CMC development and CGMP manufacturing of peptide and oligonucleotide APIs for NCEs, from early-phase development to commercialization.

Years Experience

Employees

Capacity (MT/yr)

GMP Faclities

Latest Technical Content & Literature

Explore our latest white papers and technical resources on peptide and oligonucleotide CMC, manufacturing, and regulatory strategy — insights drawn from real development and commercial-scale programs.

All CategoriesBrochuresFlyerInsights from SinopepVideosWhitepaper

Efficient Hybrid Synthesis of Amycretin

Multi-receptor agonist peptides represent one of the fastest-growing frontiers in metabolic disease therapeutics. Molecules such as amycretin, a dual GLP-1 and amylin receptor agonist, combine two...

API Substance Quality as a Determinant of Formulation Outcomes: A Review of Sodium Caprate-Enhanced Oral Semaglutide Tablet Development

Oral delivery of semaglutide is limited by low membrane permeability and gastrointestinal degradation, restricting unassisted bioavailability to well below one percent, a barrier Rybelsus® overcomes...

Reagent-Quenching for Reducing Solvent Consumption in Solid-Phase Peptide Synthesis

This paper describes a reagent-quenching strategy in which a Brønsted acid compound is introduced during the post-deprotection wash to chemically neutralize residual piperidine in situ, converting it...

In-House Biocatalytic Synthesis of Non-Canonical Amino Acids for Peptide Therapeutics

Non-canonical amino acids present a fundamentally different supply challenge compared to proteinogenic residues. Standard amino acid suppliers operate at high volume for commodity materials; NCAA...

Sinopep’s New Formulation Facility

Since its founding in 2004, Sinopep has developed a robust and scalable formulation platform focused on delivering high-quality pharmaceutical products and CDMO solutions. Our recently expanded...

Sinopep Oligonucleotide GMP Manufacturing

Our new GMP oligonucleotide facility represents a major expansion in our ability to manufacture oligonucleotide API and NCE therapeutics, including antisense oligonucleotides (ASOs) and siRNA, at...

Generic APIs Overview Flyer

Sinopep specializes in the development and CGMP manufacturing of peptide, oligonucleotide, and small molecule APIs for further processing, R&D, or compounding by licensed facilities. Our generic API...

NCE Development Brochure Download

Sinopep is a leading CDMO specializing in the development and GMP manufacturing of peptide, oligonucleotide, and small molecule NCEs. With the rapidly expanding landscape of peptide therapeutics, we...

Generic APIs Brochure

Sinopep specializes in the development and cGMP manufacturing of high-quality peptide, oligonucleotide, and small molecule active pharmaceutical ingredients (APIs) intended exclusively for further...